Body Weight  >>  Invokana (canagliflozin)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
NCT00650806: A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

Checkmark
Nov 2013 - Nov 2013: 
Completed
2
376
US
Canagliflozin (JNJ-28431754), Placebo
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
09/08
09/08
NCT02243202: Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Completed
2
335
US
Canagliflozin, INVOKANA, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
Janssen Research & Development, LLC
Obesity
06/15
06/15

Download Options